Treatment News : Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 24, 2011

Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

People with HIV who have severe hepatitis C virus (HCV)-related liver disease (cirrhosis) may be able to safely take Reyataz (atazanavir) without worsening their liver condition, according to a study published online March 17 in the journal AIDS.

Reyataz is one of the best tolerated protease inhibitors (PIs) available, and though it can cause significant elevations in a liver enzyme called bilirubin, it does not appear in clinical trials to negatively affect the liver in other ways—certainly no more so than other PIs.

While Reyataz is commonly used in people with milder forms of liver damage, some providers have expressed concerns about using it in people with cirrhosis. This is because advanced liver disease—just like Reyataz—can raise bilirubin levels. Adding Reyataz, therefore, might make it difficult to know whether a person’s increased bilirubin is being caused by Reyataz, and therefore harmless, or if the increased bilirubin is a sign of worsening disease.

To help shed light on this situation, Jose Rodriguez, MD, and his colleagues from the Hospital Ramón y Cajal in Madrid examined the medical records of 92 people coinfected with both HIV and hepatitis C virus (HCV) who had cirrhosis, 34 of whom were prescribed Reyataz at some point.

The majority were treatment experienced and had undetectable HIV levels when starting Reyataz. Roughly three quarters had a milder form of cirrhosis, and the other 26 percent had more severe cirrhosis. Most of the study participants (76 percent) used Reyataz in conjunction with low-dose Norvir (ritonavir). Only one person stopped taking Reyataz because of increases in other liver enzymes. The average length of time on Reyataz was about 15 months.

Though Reyataz did cause bilirubin elevations, the authors state that the elevations—surprisingly—were no greater than those seen in people without liver disease. Also, though people with more severe cirrhosis had higher bilirubin elevations than those with less severe cirrhosis, the difference was not large.

This finding had two practical implications. First, contrary to previous concerns, adding Reyataz did not make it difficult to determine if a person’s increased bilirubin levels were due to the drug or to worsening liver disease. Secondly, because the bilirubin increases were of a relatively small and predictable size, they did not significantly worsen a person’s model for end-stage liver disease (MELD) score, which is used to determine the urgency with which someone should receive a liver transplant.

Rodriguez and his colleagues concede that because their study did not randomly assign people to either Reyataz or another antiretroviral medication, it isn’t possible to say with certainty that it is always safe in this population, or to pinpoint those individuals who should not use it. They do state, however, that Reyataz can be safely used in at least some people with more severe liver disease.

“Atazanavir did not worsen hepatic function in more than 500 patient-months of follow-up. According to this data, [Norvir-] boosted and unboosted atazanavir could be considered a safe option in patients with cirrhosis in the clinical setting,” they conclude.

Search: Reyataz, atazanavir, hepatitis, cirrhosis, liver

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.